Swiss pharmaceutical company Roche announced Thursday its plans to purchase PathAI, a Boston-based artificial intelligence and digital pathology company, in a transaction valued at $750 million initially, with potential additional milestone-based payments totaling up to $300 million.
This purchase expands upon an existing five-year collaboration between the two companies, which was enhanced in 2024 to encompass the creation of AI-powered companion diagnostic algorithms.
The transaction is anticipated to finalize during the latter half of 2026, at which point the Massachusetts-headquartered PathAI will join Roche’s diagnostics division.
According to Roche, this purchase will bolster its standing in the digital pathology sector, an area that is revolutionizing traditional manual procedures into completely automated, artificial intelligence-powered systems.
“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” stated Matt Sause, CEO of Roche Diagnostics.
